New FTO Degrader Drug Shows Promise Against Acute Myeloid Leukemia
Researchers develop targeted drug that degrades FTO protein, disrupting ribosome production and protein synthesis in leukemia cells.
Summary
Scientists developed a novel drug that selectively degrades the FTO protein in acute myeloid leukemia (AML) cells. FTO normally removes chemical tags from RNA molecules, but when degraded by this new compound, those tags accumulate and cause critical cellular machinery for protein production to break down. The drug showed superior anti-cancer effects compared to existing FTO inhibitors in both laboratory studies and animal models. This approach targets ribosome biogenesis—the process cells use to build protein-making machinery—which is essential for cancer cell survival and growth.
Detailed Summary
Researchers at the University of Chicago and City of Hope have developed a promising new approach to treating acute myeloid leukemia (AML) by creating a drug that selectively degrades the FTO protein. FTO is an enzyme that removes m6A chemical modifications from RNA molecules, and it's been identified as a key driver of AML progression.
The team designed a targeted protein degrader that specifically eliminates FTO from cancer cells. When FTO is removed, m6A modifications accumulate on messenger RNAs that code for ribosome components—the cellular machinery responsible for protein synthesis. These modified RNAs become unstable and are rapidly degraded by another protein called YTHDF2, effectively shutting down the cancer cell's ability to produce new ribosomes.
In laboratory studies, the FTO degrader demonstrated superior anti-cancer activity compared to traditional FTO inhibitors. The compound showed selective toxicity against AML cell lines while sparing normal cells. Animal studies confirmed these promising results, with treated mice showing significant tumor regression and improved survival rates.
The research reveals a previously unknown mechanism by which FTO supports cancer growth: by maintaining the stability of ribosome biogenesis machinery. Ribosomes are essential for protein production, and cancer cells have particularly high demands for protein synthesis to support their rapid growth and division. By disrupting this fundamental cellular process, the FTO degrader effectively starves cancer cells of their protein-making capacity.
This targeted approach represents a significant advancement over existing treatments because it specifically exploits a vulnerability unique to cancer cells while leaving healthy cells largely unaffected. The findings provide both a valuable research tool for studying FTO's role in cancer and a potential foundation for developing new AML therapies.
Key Findings
- FTO degrader showed superior anti-cancer efficacy compared to FTO inhibitors in multiple AML cell lines
- Treatment increased m6A modifications on ribosome biogenesis-related mRNAs, leading to their YTHDF2-mediated decay
- Compound selectively targeted AML cells while sparing normal hematopoietic cells
- Animal studies demonstrated significant tumor regression and improved survival in treated mice
- FTO degradation disrupted ribosome biogenesis and protein translation in cancer cells
- The degrader achieved complete FTO protein elimination within 24 hours of treatment
- Ribosome biogenesis pathway genes showed significant downregulation following FTO degradation
Methodology
Researchers used proteolysis-targeting chimera (PROTAC) technology to design the FTO degrader, testing it across multiple AML cell lines and primary patient samples. In vivo studies utilized xenograft mouse models with human AML cells. The team employed RNA sequencing, mass spectrometry, and ribosome profiling to analyze molecular mechanisms. Statistical significance was determined using standard methods with appropriate controls and replicates.
Study Limitations
The study was conducted primarily in laboratory settings and animal models, requiring further clinical trials to establish safety and efficacy in humans. The research focused specifically on AML and may not apply to other cancer types. Long-term effects of FTO degradation and potential resistance mechanisms were not fully explored. The authors did not report significant conflicts of interest related to this research.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.